Project Grant R41HL184801
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $368K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stony Brook, NY 11790, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $448,250 to The Research Foundation For The State University Of New York on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate a lung-targeted immunomodulatory messenger RNA therapy for acute respiratory distress syndrome. The award funds development of an IL-10 mRNA therapeutic delivered via sulfonium lipid nanoparticles, a novel lung-targeting technology designed to suppress...
- The National Institute of Allergy and Infectious Diseases awarded Cmtx Biotech Inc. $296,470 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel liposomal formulation of rebamipide as an adjunctive host-directed treatment for Staphylococcus aureus bacteremia. Cmtx Biotech will conduct Phase I Small Business Technology Transfer research to address the high morbidity and mortality associated with S. aureus bloodstream infection, which...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $453,834 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a tissue-selective modified mRNA delivery system for cardiac injury prevention and treatment. The recipient is developing CMSMRTS 143-122, a cardiomyocyte-selective modified mRNA system encapsulated in lipid nanoparticles for intravenous administration. The system targets acid ceramidase mRNA...
- This $3,757,391 Project Grant award from the U.S. Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports the development of a field-use therapeutic for pulmonary injuries from trauma or chemical exposure. The awardee, Ceria Therapeutics Inc., is a for-profit biotechnology company that develops novel therapeutics targeting inflammation and oxidative stress. The funding will enable Ceria Therapeutics to advance its...
- The National Heart, Lung, and Blood Institute awarded Linshom Medical, Inc. $322,277 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct clinical evaluation of an alarm-activated detection system for early intervention of emerging respiratory decline using Linshom's FDA-cleared Continuous Predictive Respiratory Sensor (CPRS). The funding supports clinical development activities demonstrating the health economic value of the CPRS system, which...
- The National Heart, Lung, and Blood Institute awarded Novomedix LLC $355,963 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test novel small-molecule anti-fibrotic compounds for prevention and treatment of Duchenne muscular dystrophy cardiomyopathy. The project addresses cardiac complications in DMD patients, where improved respiratory support has extended survival into the second and third decade of life but exposed an unmet need for...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $405,966 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a multifunctional nanoparticle platform targeting galectin-3 for pulmonary fibrosis therapy. The recipient will optimize anti-fibrotic drug-containing, galectin-3-targeted poly(lactic-co-glycolic acid) nanoparticles for pulmonary delivery, building on prior results demonstrating nanoparticle...
- The National Heart, Lung, and Blood Institute awarded Tiba Biotech LLC $396,805 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, for development of lung-targeting delivery systems for small interfering RNA therapeutics. Tiba Biotech is advancing a proprietary non-viral RNA delivery platform called RNABL, which employs dendritic aminoalkyl-branched lipidoids as nanoparticle carriers. The platform addresses a critical gap in nucleic acid therapeutics: achieving...
- The National Heart, Lung, and Blood Institute awarded 3D Bioanalytix, Inc. $421,400 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance and validate a structural proteomics platform for early detection of protein misfolding–driven cardiovascular diseases. 3D Bioanalytix will optimize and validate the analytical performance and reproducibility of the Amyfold assay, a mass spectrometry–based blood test designed to detect misfolded transthyretin in...
- The National Cancer Institute awarded Matrisome Bio, Inc. $3,481,203 on September 23, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer. Matrisome Bio is developing molecularly targeted drugs based on nanobodies that specifically target disease-associated extracellular matrix (ECM) proteins highly expressed in lung cancer and other cancer indications while minimally expressed in...